Immunotherapy in triple-negative breast cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-12-18

AUTHORS

Heather Katz, Mohamed Alsharedi

ABSTRACT

Breast cancer can be classified based on the expression or lack of expression of protein receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (Her2). The basal molecular subtype is mostly made up of breast cancers that do not express ER/PR or Her2, triple-negative breast cancers (TNBC) (Bertucci et al. in Int J Cancer 123(1):236, 2008). TNBC tends to be more aggressive as there are no approved targeted treatments and the only treatment option currently is cytotoxic chemotherapy. Recent data show that some chemotherapies, specifically anthracyclines, not only have cytotoxic effects but also use the immune system by activating CD8+ T cell responses to kill cancer cells (Stagg et al. in Ther Adv Med Oncol 5(3):169–181, 2013), and thus, tumor-infiltrating lymphocytes respond well to chemotherapy. Currently, systemic immunotherapy which utilizes the patient’s own immune system directly to eradicate and target neoplastic cells is being explored as treatment for TNBC as this type of breast cancer has been shown to be immunogenic (Yu et al. in Int J Environ Res Public Health 14:68, 2017). According to the Cancer Genome Atlas, TNBC has higher PD-L1 mRNA expression (Mittendorf et al. Cancer Immunol Res 2(4):361–370, 2014). Higher rates of CD8+ T cell infiltration were also found in TNBC according to a study by Liu et al. (Breast Cancer Res 14:R48, 2012). In TNBC patients, Pembrolizumab, a monoclonal antibody that targets programmed cell death protein 1 (PD-1), and Atezolizumab, a monoclonal antibody that targets its ligand, have been investigated to assess dose tolerability and side effects. Further studies involving vaccines, immunotherapy that targets cytotoxic T lymphocyte-associated protein-4 and PD-L1, are currently being investigated for treatment of TNBC. This review outlines the systemic immunotherapies that are currently being investigated for patients with TNBC. More... »

PAGES

13

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-017-1071-6

DOI

http://dx.doi.org/10.1007/s12032-017-1071-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1099709359

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29255938


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "B7-H1 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CTLA-4 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Programmed Cell Death 1 Receptor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triple Negative Breast Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology-Oncology, Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA", 
          "id": "http://www.grid.ac/institutes/grid.259676.9", 
          "name": [
            "Division of Hematology-Oncology, Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Katz", 
        "givenName": "Heather", 
        "id": "sg:person.011543016727.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543016727.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA", 
          "id": "http://www.grid.ac/institutes/grid.490061.a", 
          "name": [
            "Division of Hematology-Oncology, Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA", 
            "Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alsharedi", 
        "givenName": "Mohamed", 
        "id": "sg:person.01037220762.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037220762.97"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrc3239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047946992", 
          "https://doi.org/10.1038/nrc3239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-007-9632-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039484580", 
          "https://doi.org/10.1007/s10549-007-9632-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr3148", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014237989", 
          "https://doi.org/10.1186/bcr3148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10552-009-9331-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014892537", 
          "https://doi.org/10.1007/s10552-009-9331-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-017-4537-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092335703", 
          "https://doi.org/10.1007/s10549-017-4537-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12026-011-8224-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032641792", 
          "https://doi.org/10.1007/s12026-011-8224-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12-18", 
    "datePublishedReg": "2017-12-18", 
    "description": "Breast cancer can be classified based on the expression or lack of expression of protein receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (Her2). The basal molecular subtype is mostly made up of breast cancers that do not express ER/PR or Her2, triple-negative breast cancers (TNBC) (Bertucci et al. in Int J Cancer 123(1):236, 2008). TNBC tends to be more aggressive as there are no approved targeted treatments and the only treatment option currently is cytotoxic chemotherapy. Recent data show that some chemotherapies, specifically anthracyclines, not only have cytotoxic effects but also use the immune system by activating CD8+ T cell responses to kill cancer cells (Stagg et al. in Ther Adv Med Oncol 5(3):169\u2013181, 2013), and thus, tumor-infiltrating lymphocytes respond well to chemotherapy. Currently, systemic immunotherapy which utilizes the patient\u2019s own immune system directly to eradicate and target neoplastic cells is being explored as treatment for TNBC as this type of breast cancer has been shown to be immunogenic (Yu et al. in Int J Environ Res Public Health 14:68, 2017). According to the Cancer Genome Atlas, TNBC has higher PD-L1 mRNA expression (Mittendorf et al. Cancer Immunol Res 2(4):361\u2013370, 2014). Higher rates of CD8+ T cell infiltration were also found in TNBC according to a study by Liu et al. (Breast Cancer Res 14:R48, 2012). In TNBC patients, Pembrolizumab, a monoclonal antibody that targets programmed cell death protein 1 (PD-1), and Atezolizumab, a monoclonal antibody that targets its ligand, have been investigated to assess dose tolerability and side effects. Further studies involving vaccines, immunotherapy that targets cytotoxic T lymphocyte-associated protein-4 and PD-L1, are currently being investigated for treatment of TNBC. This review outlines the systemic immunotherapies that are currently being investigated for patients with TNBC.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12032-017-1071-6", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "keywords": [
      "triple-negative breast cancer", 
      "own immune system", 
      "breast cancer", 
      "progesterone receptor", 
      "systemic immunotherapy", 
      "estrogen receptor", 
      "cytotoxic T-lymphocyte-associated protein 4", 
      "immune system", 
      "T-lymphocyte-associated protein 4", 
      "human epidermal growth receptor 2", 
      "ER/progesterone receptor", 
      "patient's own immune system", 
      "treatment of TNBC", 
      "cell death protein 1", 
      "PD-L1 mRNA expression", 
      "monoclonal antibodies", 
      "high PD-L1 mRNA expression", 
      "basal molecular subtype", 
      "tumor-infiltrating lymphocytes", 
      "T cell infiltration", 
      "only treatment option", 
      "T cell responses", 
      "death protein 1", 
      "cytotoxic chemotherapy", 
      "Cancer Genome Atlas", 
      "TNBC patients", 
      "PD-L1", 
      "treatment options", 
      "cell infiltration", 
      "lack of expression", 
      "molecular subtypes", 
      "dose tolerability", 
      "receptor 2", 
      "side effects", 
      "immunotherapy", 
      "neoplastic cells", 
      "cell responses", 
      "cancer", 
      "mRNA expression", 
      "chemotherapy", 
      "cancer cells", 
      "protein 4", 
      "Genome Atlas", 
      "protein 1", 
      "cytotoxic effects", 
      "CD8", 
      "receptors", 
      "Further studies", 
      "patients", 
      "recent data", 
      "high rate", 
      "treatment", 
      "antibodies", 
      "expression", 
      "pembrolizumab", 
      "atezolizumab", 
      "tolerability", 
      "cells", 
      "protein receptors", 
      "HER2", 
      "lymphocytes", 
      "anthracyclines", 
      "vaccine", 
      "subtypes", 
      "infiltration", 
      "study", 
      "effect", 
      "review", 
      "options", 
      "response", 
      "atlas", 
      "rate", 
      "lack", 
      "data", 
      "types", 
      "ligands", 
      "system", 
      "et al", 
      "al", 
      "Liu et al"
    ], 
    "name": "Immunotherapy in triple-negative breast cancer", 
    "pagination": "13", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1099709359"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-017-1071-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29255938"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-017-1071-6", 
      "https://app.dimensions.ai/details/publication/pub.1099709359"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_738.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12032-017-1071-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-017-1071-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-017-1071-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-017-1071-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-017-1071-6'


 

This table displays all metadata directly associated to this object as RDF triples.

220 TRIPLES      21 PREDICATES      122 URIs      107 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-017-1071-6 schema:about N33c52efb8a584af6ad5d771fa682d380
2 N36e06b699a4d48d79e782e82d2e1b6e2
3 N4a31f37bf7ed4be2be62329e5dfb746d
4 Na94748c306bd424aa2a022820b9db04d
5 Nb08c5d79edf24a9695501eb919329dc3
6 Nb3e6548faa674108a21c22877b926618
7 Nc5a2f0833b8e43bfb191e3de06708f17
8 Nd0eb958c33e84e71a9abc5e68113332d
9 Nd3541eb60e0e4d99b59237eaa98bce2e
10 Ndbf24f39b554497aac6d3541f99864e5
11 anzsrc-for:11
12 anzsrc-for:1107
13 anzsrc-for:1112
14 schema:author N4f4ef0b832934775bcc798036aed1482
15 schema:citation sg:pub.10.1007/s10549-007-9632-6
16 sg:pub.10.1007/s10549-017-4537-5
17 sg:pub.10.1007/s10552-009-9331-1
18 sg:pub.10.1007/s12026-011-8224-z
19 sg:pub.10.1038/nrc3239
20 sg:pub.10.1186/bcr3148
21 schema:datePublished 2017-12-18
22 schema:datePublishedReg 2017-12-18
23 schema:description Breast cancer can be classified based on the expression or lack of expression of protein receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (Her2). The basal molecular subtype is mostly made up of breast cancers that do not express ER/PR or Her2, triple-negative breast cancers (TNBC) (Bertucci et al. in Int J Cancer 123(1):236, 2008). TNBC tends to be more aggressive as there are no approved targeted treatments and the only treatment option currently is cytotoxic chemotherapy. Recent data show that some chemotherapies, specifically anthracyclines, not only have cytotoxic effects but also use the immune system by activating CD8+ T cell responses to kill cancer cells (Stagg et al. in Ther Adv Med Oncol 5(3):169–181, 2013), and thus, tumor-infiltrating lymphocytes respond well to chemotherapy. Currently, systemic immunotherapy which utilizes the patient’s own immune system directly to eradicate and target neoplastic cells is being explored as treatment for TNBC as this type of breast cancer has been shown to be immunogenic (Yu et al. in Int J Environ Res Public Health 14:68, 2017). According to the Cancer Genome Atlas, TNBC has higher PD-L1 mRNA expression (Mittendorf et al. Cancer Immunol Res 2(4):361–370, 2014). Higher rates of CD8+ T cell infiltration were also found in TNBC according to a study by Liu et al. (Breast Cancer Res 14:R48, 2012). In TNBC patients, Pembrolizumab, a monoclonal antibody that targets programmed cell death protein 1 (PD-1), and Atezolizumab, a monoclonal antibody that targets its ligand, have been investigated to assess dose tolerability and side effects. Further studies involving vaccines, immunotherapy that targets cytotoxic T lymphocyte-associated protein-4 and PD-L1, are currently being investigated for treatment of TNBC. This review outlines the systemic immunotherapies that are currently being investigated for patients with TNBC.
24 schema:genre article
25 schema:isAccessibleForFree false
26 schema:isPartOf Na458c0a6bce94edbba85ce66683e0e9e
27 Nfa2338f0ecda41e8a19eee8746d899c8
28 sg:journal.1094524
29 schema:keywords CD8
30 Cancer Genome Atlas
31 ER/progesterone receptor
32 Further studies
33 Genome Atlas
34 HER2
35 Liu et al
36 PD-L1
37 PD-L1 mRNA expression
38 T cell infiltration
39 T cell responses
40 T-lymphocyte-associated protein 4
41 TNBC patients
42 al
43 anthracyclines
44 antibodies
45 atezolizumab
46 atlas
47 basal molecular subtype
48 breast cancer
49 cancer
50 cancer cells
51 cell death protein 1
52 cell infiltration
53 cell responses
54 cells
55 chemotherapy
56 cytotoxic T-lymphocyte-associated protein 4
57 cytotoxic chemotherapy
58 cytotoxic effects
59 data
60 death protein 1
61 dose tolerability
62 effect
63 estrogen receptor
64 et al
65 expression
66 high PD-L1 mRNA expression
67 high rate
68 human epidermal growth receptor 2
69 immune system
70 immunotherapy
71 infiltration
72 lack
73 lack of expression
74 ligands
75 lymphocytes
76 mRNA expression
77 molecular subtypes
78 monoclonal antibodies
79 neoplastic cells
80 only treatment option
81 options
82 own immune system
83 patient's own immune system
84 patients
85 pembrolizumab
86 progesterone receptor
87 protein 1
88 protein 4
89 protein receptors
90 rate
91 recent data
92 receptor 2
93 receptors
94 response
95 review
96 side effects
97 study
98 subtypes
99 system
100 systemic immunotherapy
101 tolerability
102 treatment
103 treatment of TNBC
104 treatment options
105 triple-negative breast cancer
106 tumor-infiltrating lymphocytes
107 types
108 vaccine
109 schema:name Immunotherapy in triple-negative breast cancer
110 schema:pagination 13
111 schema:productId N6e0980da63d24985a7e03a2a369eb17e
112 Nc5553a9bb85741a8b027ea0e448207eb
113 Nd6968fd87b0d43698a696e61f9e43247
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099709359
115 https://doi.org/10.1007/s12032-017-1071-6
116 schema:sdDatePublished 2022-11-24T21:02
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher N6f2edc7502f844cdb80380ef3227645b
119 schema:url https://doi.org/10.1007/s12032-017-1071-6
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N33c52efb8a584af6ad5d771fa682d380 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name CTLA-4 Antigen
125 rdf:type schema:DefinedTerm
126 N36e06b699a4d48d79e782e82d2e1b6e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Female
128 rdf:type schema:DefinedTerm
129 N4a31f37bf7ed4be2be62329e5dfb746d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Programmed Cell Death 1 Receptor
131 rdf:type schema:DefinedTerm
132 N4f4ef0b832934775bcc798036aed1482 rdf:first sg:person.011543016727.10
133 rdf:rest N925903350c2d4d5ca3d986948ec5d46b
134 N6e0980da63d24985a7e03a2a369eb17e schema:name pubmed_id
135 schema:value 29255938
136 rdf:type schema:PropertyValue
137 N6f2edc7502f844cdb80380ef3227645b schema:name Springer Nature - SN SciGraph project
138 rdf:type schema:Organization
139 N925903350c2d4d5ca3d986948ec5d46b rdf:first sg:person.01037220762.97
140 rdf:rest rdf:nil
141 Na458c0a6bce94edbba85ce66683e0e9e schema:issueNumber 1
142 rdf:type schema:PublicationIssue
143 Na94748c306bd424aa2a022820b9db04d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Antibodies, Monoclonal
145 rdf:type schema:DefinedTerm
146 Nb08c5d79edf24a9695501eb919329dc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 Nb3e6548faa674108a21c22877b926618 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name B7-H1 Antigen
151 rdf:type schema:DefinedTerm
152 Nc5553a9bb85741a8b027ea0e448207eb schema:name doi
153 schema:value 10.1007/s12032-017-1071-6
154 rdf:type schema:PropertyValue
155 Nc5a2f0833b8e43bfb191e3de06708f17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Triple Negative Breast Neoplasms
157 rdf:type schema:DefinedTerm
158 Nd0eb958c33e84e71a9abc5e68113332d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Antineoplastic Agents, Immunological
160 rdf:type schema:DefinedTerm
161 Nd3541eb60e0e4d99b59237eaa98bce2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Immunotherapy
163 rdf:type schema:DefinedTerm
164 Nd6968fd87b0d43698a696e61f9e43247 schema:name dimensions_id
165 schema:value pub.1099709359
166 rdf:type schema:PropertyValue
167 Ndbf24f39b554497aac6d3541f99864e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Antineoplastic Agents
169 rdf:type schema:DefinedTerm
170 Nfa2338f0ecda41e8a19eee8746d899c8 schema:volumeNumber 35
171 rdf:type schema:PublicationVolume
172 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
173 schema:name Medical and Health Sciences
174 rdf:type schema:DefinedTerm
175 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
176 schema:name Immunology
177 rdf:type schema:DefinedTerm
178 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
179 schema:name Oncology and Carcinogenesis
180 rdf:type schema:DefinedTerm
181 sg:journal.1094524 schema:issn 1357-0560
182 1559-131X
183 schema:name Medical Oncology
184 schema:publisher Springer Nature
185 rdf:type schema:Periodical
186 sg:person.01037220762.97 schema:affiliation grid-institutes:grid.490061.a
187 schema:familyName Alsharedi
188 schema:givenName Mohamed
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037220762.97
190 rdf:type schema:Person
191 sg:person.011543016727.10 schema:affiliation grid-institutes:grid.259676.9
192 schema:familyName Katz
193 schema:givenName Heather
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011543016727.10
195 rdf:type schema:Person
196 sg:pub.10.1007/s10549-007-9632-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039484580
197 https://doi.org/10.1007/s10549-007-9632-6
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s10549-017-4537-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092335703
200 https://doi.org/10.1007/s10549-017-4537-5
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s10552-009-9331-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014892537
203 https://doi.org/10.1007/s10552-009-9331-1
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s12026-011-8224-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1032641792
206 https://doi.org/10.1007/s12026-011-8224-z
207 rdf:type schema:CreativeWork
208 sg:pub.10.1038/nrc3239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047946992
209 https://doi.org/10.1038/nrc3239
210 rdf:type schema:CreativeWork
211 sg:pub.10.1186/bcr3148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014237989
212 https://doi.org/10.1186/bcr3148
213 rdf:type schema:CreativeWork
214 grid-institutes:grid.259676.9 schema:alternateName Division of Hematology-Oncology, Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA
215 schema:name Division of Hematology-Oncology, Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA
216 rdf:type schema:Organization
217 grid-institutes:grid.490061.a schema:alternateName Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA
218 schema:name Division of Hematology-Oncology, Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr, 25701, Huntington, WV, USA
219 Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, 1400 Hal Greer Blvd., 25701, Huntington, WV, USA
220 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...